CNS International Prognostic Index in Diffuse Large B-Cell Lymphoma (CNS-IPI)

Estimate risk of CNS relapse/progression in diffuse large B-cell lymphoma


CNS recurrence/progression in patients with DLBCL can be devastating. Although some studies suggest a decline in the occurrence of CNS relapse in the rituximab era, certain high risk groups can still be identified and should be considered for CNS-directed trials or prophylactic therapies.

The CNS-IPI was derived from a population of patients (n=2164) enrolled in the German clinical trials and subsequently validated in a population of 1597 patients treated in British Columbia, Canada. The score is based on the original IPI factors with the addition of kidney and/or adrenal involvement. The final score is able to differentiate patients into 3 distinct prognostic groups for CNS recurrence/progression.


Schmitz, et al.

Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2016 September 10, 34 (26): 3150-6

By using this site you acknowledge that you have read, understand, and agree to be bound by our terms of use and privacy policy. All content and tools are for educational use only, are not meant to be a substitute for professional advice and should not be used for medical diagnosis and/or medical treatment.

1. Age?

0/6 completed